Three scientists who revolutionized the treatment of cystic fibrosis and prolonged the lifespan of patients with the deadly disease have won the Lasker Award, one of the most prestigious awards in medicine. Boston-based Vertex Pharmaceuticals researcher Paul Negulescu, former Vertex researcher Jesús (Tito) González, and University of Iowa professor Michael Welsh, will share the $250,000 prize. The Lasker DeBakey Clinical …
Read More »
Vertex Pharmaceuticals said Monday afternoon that its next-generation non-opioid pain reliever failed to significantly outperform placebo in a Phase 2 trial. The experimental drug, codenamed VX-993, is similar to the company’s recently approved pill Journavx but could potentially be given at higher doses and formulated as an IV infusion. The hope is that it could thus provide superior relief or …
Read More »Vertex Stock Tumbles 15% After Strong Earnings. What’s Spooking Investors. Barron’s Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings The Wall Street Journal Vertex’s trial failure, scrapped study cloud pain drug push; shares slump Reuters Vertex’s top scientist Altshuler to retire, next-generation pain drug fails Endpoints News Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain Yahoo Finance …
Read More »Palantir, Vertex, Hims & Hers, AMD, BP, and More Stock Market Movers Barron’s Stocks making the biggest moves after hours: Palantir, Hims & Hers Health, Vertex Pharmaceuticals and more CNBC Stock Market Today: Dow, S&P 500 and Nasdaq look to extend the rebound as Treasury yields steady ahead of services surveys; Palantir shares hit record after earnings. MarketWatch Biggest stock movers Tuesday: PLTR, …
Read More »Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings The Wall Street Journal Vertex next-generation pain candidate fails Phase 2 trial statnews.com Vertex shares plummet 15% as next-gen painkiller misses target The Business Journals Vertex drops aspiring Journavx follower in acute pain after phase 2 failure Fierce Biotech Vertex’s pain portfolio is pummeled with setbacks FirstWord Pharma Source link
Read More »